A detailed history of Signaturefd, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 538 shares of ITCI stock, worth $45,982. This represents 0.0% of its overall portfolio holdings.

Number of Shares
538
Previous 530 1.51%
Holding current value
$45,982
Previous $36,000 8.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$67.99 - $80.84 $543 - $646
8 Added 1.51%
538 $39,000
Q2 2024

Jul 29, 2024

BUY
$64.76 - $79.84 $3,497 - $4,311
54 Added 11.34%
530 $36,000
Q1 2024

May 03, 2024

SELL
$64.37 - $75.65 $2,703 - $3,177
-42 Reduced 8.11%
476 $32,000
Q4 2023

Jan 31, 2024

BUY
$46.37 - $73.65 $11,082 - $17,602
239 Added 85.66%
518 $37,000
Q3 2023

Nov 03, 2023

SELL
$52.09 - $64.1 $3,698 - $4,551
-71 Reduced 20.29%
279 $14,000
Q2 2023

Aug 01, 2023

BUY
$54.67 - $66.44 $3,280 - $3,986
60 Added 20.69%
350 $22,000
Q1 2023

Apr 28, 2023

BUY
$43.8 - $56.99 $963 - $1,253
22 Added 8.21%
290 $15,000
Q4 2022

Jan 27, 2023

BUY
$44.07 - $54.45 $5,640 - $6,969
128 Added 91.43%
268 $14,000
Q3 2022

Nov 08, 2022

BUY
$42.7 - $59.99 $2,305 - $3,239
54 Added 62.79%
140 $7,000
Q2 2022

Aug 10, 2022

SELL
$43.0 - $65.64 $6,665 - $10,174
-155 Reduced 64.32%
86 $5,000
Q1 2022

May 02, 2022

BUY
$38.74 - $62.09 $5,462 - $8,754
141 Added 141.0%
241 $15,000
Q4 2021

Jan 25, 2022

BUY
$35.2 - $53.42 $1,196 - $1,816
34 Added 51.52%
100 $5,000
Q3 2021

Oct 28, 2021

SELL
$28.72 - $42.49 $258 - $382
-9 Reduced 12.0%
66 $2,000
Q2 2021

Jul 26, 2021

BUY
$29.3 - $44.5 $1,318 - $2,002
45 Added 150.0%
75 $3,000
Q1 2021

Apr 30, 2021

BUY
$30.8 - $39.51 $924 - $1,185
30 New
30 $1,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.07B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Signaturefd, LLC Portfolio

Follow Signaturefd, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.